Stay updated on Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Sign up to get notified when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FVxxx6vmKc-I2LUHLA6XUjY-2Ty8.uncropped.jpg&w=3840&q=75)
Latest updates to the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe website has been updated to version 2.10.0, adding two more study numbers and indicating that the study now has 72 locations, while the previous version 2.9.7 has been removed.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check18 days agoChange DetectedA new study on Semaglutide once weekly as an add-on to SGLT-2 inhibitor therapy in type 2 diabetes was published in Lancet Diabetes Endocrinology in May 2019, with subsequent errata and updates in August and November 2019.SummaryDifference0.2%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Revision has changed from v2.9.3 to v2.9.5, indicating an update or modification to the content of the webpage.SummaryDifference0.0%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.0%
Stay in the know with updates to Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.